Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease

Abstract

Cerebral amyloid-β (Aβ) accumulation due to impaired Aβ clearance is a pivotal event in the pathogenesis of Alzheimer's disease (AD). Considerable brain-derived Aβ is cleared via transporting to the periphery. The liver is the largest organ responsible for the clearance of metabolites in the periphery. Whether the liver physiologically clears circulating Aβ and its therapeutic potential for AD remains unclear. Here, we found that about 13.9% of Aβ42 and 8.9% of Aβ40 were removed from the blood when flowing through the liver, and this capacity was decreased with Aβ receptor LRP-1 expression down-regulated in hepatocytes in the aged animals. Partial blockage of hepatic blood flow increased Aβ levels in both blood and brain interstitial fluid. The chronic decline in hepatic Aβ clearance via LRP-1 knockdown specific in hepatocytes aggravated cerebral Aβ burden and cognitive deficits, while enhancing hepatic Aβ clearance via LRP-1 overexpression attenuated cerebral Aβ deposition and cognitive impairments in APP/PS1 mice. Our findings demonstrate that the liver physiologically clears blood Aβ and regulates brain Aβ levels, suggesting that a decline of hepatic Aβ clearance during aging could be involved in AD development, and hepatic Aβ clearance is a novel therapeutic approach for AD.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00401-023-02559-z

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9–21. https://doi.org/10.1056/NEJMoa2212948 · DOI · Paper page

Cited by

See all 110

Metadata

Authors
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., Sun, P.-Y., Zeng, G.-H., Shen, Y.-Y., Shi, A.-Y., Jin, W.-S., Bu, X.-L., Liu, H.-M., Xu, Y.-M., Wang, J., & Wang, Y.-J.
Affiliations
  • Shanghai Medical College of Fudan University (CN)
  • Army Medical University (CN)
Corresponding author
  • Xu, Man-Yu
  • Wang, Jun
  • Wang, Yan-Jiang
Venue
Acta Neuropathologica
Published
2023-03-25
Volume
145
Issue
6
Pages
717-731
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W4360821293
Cited by
110
References
44
Citations by year
2026: 34 · 2025: 32 · 2024: 33 · 2023: 11
FWCI
10.73
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Acta Neuropathologica (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81930028, 31921003)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
amyloid-beta clearance, liver, Alzheimer's disease, LRP1, hepatocytes, hepatic blood flow, aging, amyloid-beta 42, Aβ40, APP/PS1 mice, cognitive impairment, therapeutic target
MeSH terms
Alzheimer Disease, Animals, Brain, Disease Models, Animal, Liver, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s00401-023-02559-z
The paper
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., Sun, P.-Y., Zeng, G.-H., Shen, Y.-Y., Shi, A.-Y., Jin, W.-S., Bu, X.-L., Liu, H.-M., Xu, Y.-M., Wang, J., & Wang, Y.-J. (2023). Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-023-02559-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.